London, UK 3 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be conducting a phase II clinical trial to assess the safety and tolerability of COMP360 psilocybin therapy in post-traumatic stress disorder . The study expands COMPASS’s research pipeline in psilocybin therapy with COMP360, .
Translating presence into power thehill.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehill.com Daily Mail and Mail on Sunday newspapers.
(0)
LONDON, June 03, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS) ( COMPASS ), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult volunteers with support from specially trained therapists.
The data) from the randomised, double-blind, placebo-controlled, phase I trial conducted at King s College London, will be presented today at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, by Dr James Rucker, Consultant Psychiatrist and Senior Clinical Lecturer in Psychopharmacology at King s College London s Institute of Psychiatry, Psychology and Neuroscience (IoPPN). Initial results from the study were published in December 2019. The results published today present a more in-depth analysis of cognitive
COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers
COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult volunteers with support from specially trained therapists. The data from the randomised, …
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult volunteers with support from specially trained therapists.
How Mastercard s Rules Against Child Pornographers Could Be Used to Ban Conservatives From Banking amren.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from amren.com Daily Mail and Mail on Sunday newspapers.